John Bilbrey Net Worth

The estimated Net Worth of John P Bilbrey is at least $5.88 Million dollars as of 1 May 2024. Mr. Bilbrey owns over 6,329 units of Elanco Animal Health Inc stock worth over $529,461 and over the last 21 years he sold ELAN stock worth over $5,042,512. In addition, he makes $306,676 as Independent Director at Elanco Animal Health Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Bilbrey ELAN stock SEC Form 4 insiders trading

John has made over 37 trades of the Elanco Animal Health Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 6,329 units of ELAN stock worth $392,651 on 1 May 2024.

The largest trade he's ever made was exercising 102,615 units of Elanco Animal Health Inc stock on 17 March 2014 worth over $4,952,200. On average, John trades about 1,603 units every 19 days since 2003. As of 1 May 2024 he still owns at least 36,565 units of Elanco Animal Health Inc stock.

You can see the complete history of Mr. Bilbrey stock trades at the bottom of the page.

John Bilbrey biography

John P. Bilbrey is Independent Director of the company. He served as the CEO and President of The Hershey Company, a multinational consumer food company, from 2011 until his retirement in 2017, and as Chairman of the Board from 2015 until 2018. Previously, Bilbrey served in various roles at The Hershey Company, including as the Chief Operating Officer and EVP from 2010 to 2011, the President of North America from 2007 to 2010, the President of International Commercial group from 2005 to 2007. Prior to joining The Hershey Company, he held leadership positions at Mission Foods, Danone Waters of North America, Inc., Bilbrey Farms and Ranch and Procter & Gamble Company. Mr. Bilbrey currently serves on the board of directors of Colgate-Palmolive Company and Campbell Soup Company, and has previously served on the boards of directors of The Hershey Company and McCormick & Company, Incorporated.

What is the salary of John Bilbrey?

As the Independent Director of Elanco Animal Health Inc, the total compensation of John Bilbrey at Elanco Animal Health Inc is $306,676. There are 12 executives at Elanco Animal Health Inc getting paid more, with Jeffrey Simmons having the highest compensation of $15,801,800.

How old is John Bilbrey?

John Bilbrey is 64, he's been the Independent Director of Elanco Animal Health Inc since 2019. There are 2 older and 26 younger executives at Elanco Animal Health Inc. The oldest executive at Elanco Animal Health Inc is R. David Hoover, 74, who is the Independent Chairman of the Board.

Insiders trading at Elanco Animal Health Inc

Over the last 6 years, insiders at Elanco Animal Health Inc have traded over $1,626,280,000 worth of Elanco Animal Health Inc stock and bought 657,104 units worth $14,225,149 . The most active insiders traders include Aktiengesellschaft Bayer Wo..., Scott D.Sachem Head Capital..., and R David Hoover. On average, Elanco Animal Health Inc executives and independent directors trade stock every 38 days with the average trade being worth of $14,011,833. The most recent stock trade was executed by Michael J Harrington on 22 August 2024, trading 3,500 units of ELAN stock currently worth $51,975.

What does Elanco Animal Health Inc do?

elanco is a global animal health company. our vision: food and companionship enriching life. elanco fulfills this vision through three primary pursuits: - helping deliver a safe, more affordable, more abundant food supply by improving the health and performance of animals - helping pets live longer, healthier, higher-quality lives - improving food safety elanco employees are empowered to preserve elanco’s common culture of humility, discipline and involvement. we have a responsibility to connect and contribute to our cause, to be passionate about delivering solutions and value to our customers, and to embrace opportunities for personal and professional growth and development. through innovative products, quality systems and a shared vision, elanco strives daily to enhance animal health—and enrich the lives of people worldwide.

Complete history of Mr. Bilbrey stock trades at Campbell Soup Co, Colgate-Palmolive Co, Hershey, McCormick & Co, McCormick, Tapestry Inc, and Elanco Animal Health Inc

Elanco Animal Health Inc executives and stock owners

Elanco Animal Health Inc executives and other stock owners filed with the SEC include:

• Jeffrey Simmons,
  President, Chief Executive Officer, Director
• Sarena Lin,
  Executive Vice President, Global Marketing, Corporate Strategy and Transformation
• David Kinard,
  Executive Vice President of Human Resources
• David Urbanek,
  Executive Vice President - Manufacturing, Quality
• Aaron Schacht,
  Executive Vice President - Innovation, Regulatory, Business Development
• Todd Young,
  Chief Financial Officer, Executive Vice President
• Jeffrey N. Simmons,
  Pres, CEO & Director
• Todd S. Young,
  Exec. VP of Corp. Governance and Strategy & CFO
• R. David Hoover,
  Independent Chairman of the Board
• Kapila Anand,
  Independent Director
• Lawrence Kurzius,
  Independent Director
• Michael Harrington,
  Independent Director
• John Bilbrey,
  Independent Director
• Denise Scots-Knight,
  Independent Director
• Kirk McDonald,
  Independent Director
• Deborah Kochevar,
  Independent Director
• Art Garcia,
  Independent Director
• Joshua Smiley,
  Independent Director
• Aarti Shah,
  Independent Director
• David Ricks,
  Independent Director
• Carl McMillian,
  Independent Director
• James Meer,
  Chief Accounting Officer, Vice President
• Ramiro Cabral,
  Executive Vice President - Elanco International
• Michael-Bryant Hicks,
  Executive Vice President, General Counsel, Corporate Secretary
• Larbi Van Lier,
  Sr. VP of Asia
• Shawn McKee,
  Sr. VP of U.S. Companion Animal
• David Alan Urbanek,
  Exec. VP of Manufacturing & Quality
• Ramiro Martin Cabral,
  Exec. VP of Elanco International
• Racquel Harris Mason,
  Exec. VP & Chief Marketing Officer
• Marcela A. Kirberger,
  Exec. VP, Gen. Counsel & Corp. Sec.
• Tiffany Ann Kanaga,
  Head of Investor Relations
• David S. Kinard,
  Exec. VP of HR Corp. Affairs & Admin.
• Chris Keeley,
  Sr. VP & Chief Information Officer
• James M. Meer,
  VP & Chief Accounting Officer
• De Simas Jose Manuel Correia,
  SEE REMARKS
• Lilly & Co Eli,
  10% owner
• Timothy J Bettington,
  SEE REMARKS
• Aktiengesellschaft Bayer Wo...,
  
• Racquel Harris Mason,
  See Remarks
• Dirk Ehle,
  Ex VP & Pres Elanco Europe
• Joyce J. Lee,
  Ex VP Prs US Pet Hlth Com Op
• Rajeev A. Modi,
  SEE REMARKS
• Paul Herendeen,
  
• Marcela A. Kirberger,
  SEE REMARKS
• William F Doyle,
  
• Scott D.Sachem Head Capital...,
  
• Brabander Ellen De,
  SEE REMARKS
• Shiv O'neill,
  GC AND CORP SEC
• Grace Mc Ardle,
  EVP, MANUFACTURING AND QUALITY